MODIFICATION TO MAMMAPRINT

Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer

AGENDIA BV

The following data is part of a premarket notification filed by Agendia Bv with the FDA for Modification To Mammaprint.

Pre-market Notification Details

Device IDK080252
510k NumberK080252
Device Name:MODIFICATION TO MAMMAPRINT
ClassificationClassifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer
Applicant AGENDIA BV LOUWESWEG 6 Amsterdam,  NL 1066 Ec
ContactGuido Brink
CorrespondentGuido Brink
AGENDIA BV LOUWESWEG 6 Amsterdam,  NL 1066 Ec
Product CodeNYI  
CFR Regulation Number866.6040 [🔎]
DecisionSubstantially Equivalent (SESE)
TypeTraditional
3rd Party ReviewedNo
Combination ProductNo
Date Received2008-01-31
Decision Date2008-07-21
Summary:summary

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.